Symbols / IMUX $1.07 -2.29% Immunic, Inc.

Healthcare • Biotechnology • United States • NCM
IMUX Chart
About

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 138.95M
Enterprise Value 127.30M Income -97.17M Sales —
Book/sh -0.06 Cash/sh 0.12 Dividend Yield —
Payout 0.00% Employees 92 IPO —
P/E — Forward P/E -3.07 PEG —
P/S — P/B -19.36 P/C —
EV/EBITDA -1.24 EV/Sales — Quick Ratio 0.64
Current Ratio 0.75 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.62 EPS next Y -0.35 EPS Growth —
Revenue Growth — Earnings 2026-05-14 ROA -198.76%
ROE -16.53% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 130.46M
Shs Float 121.08M Short Float 7.41% Short Ratio 1.28
Short Interest — 52W High 1.51 52W Low 0.51
Beta 1.48 Avg Volume 3.52M Volume 1.40M
Target Price $5.25 Recom Strong_buy Prev Close $1.09
Price $1.06 Change -2.29%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.25
Mean price target
2. Current target
$1.07
Latest analyst target
3. DCF / Fair value
$-6.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.07
Low
$3.00
High
$10.00
Mean
$5.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 init Guggenheim — → Buy $7
2026-03-02 main HC Wainwright & Co. Buy → Buy $5
2026-02-13 main D. Boral Capital Buy → Buy $4
2026-02-09 reit HC Wainwright & Co. Buy → Buy $8
2026-01-07 main D. Boral Capital Buy → Buy $8
2025-11-14 main HC Wainwright & Co. Buy → Buy $8
2025-11-13 main D. Boral Capital Buy → Buy $8
2025-09-29 init Chardan Capital — → Buy $3
2025-09-26 reit HC Wainwright & Co. Buy → Buy $10
2025-09-25 main D. Boral Capital Buy → Buy $10
2025-08-08 main D. Boral Capital Buy → Buy $10
2025-06-25 main D. Boral Capital Buy → Buy $10
2025-06-05 main D. Boral Capital Buy → Buy $10
2025-05-29 main D. Boral Capital Buy → Buy $10
2025-05-23 reit B. Riley Securities Buy → Buy $5
2025-05-01 reit HC Wainwright & Co. Buy → Buy $10
2025-04-30 main D. Boral Capital Buy → Buy $17
2025-04-16 reit B. Riley Securities Buy → Buy $6
2025-04-15 reit HC Wainwright & Co. Buy → Buy $10
2025-04-10 main D. Boral Capital Buy → Buy $17
News
RSS: Latest IMUX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-06-13 NASH DUANE D Officer and Director — 20,000 $0.83 $16,694
2025-06-05 NEERMANN JOERG Director — 100,000 $0.76 $76,700
2025-06-05 TARDIO JASON President — 12,512 $0.79 $9,884
2025-06-05 TARDIO JASON President — 12,512 $0.79 $9,884
2025-06-04 VITT DANIEL Chief Executive Officer — 15,000 $0.77 $11,550
2025-06-04 VITT DANIEL Officer and Director — 15,000 $0.77 $11,550
2025-06-03 WHALEY GLENN Chief Financial Officer — 45,000 $0.71 $32,076
2025-06-03 RUDICK RICHARD ALAN Director — 143,075 $0.70 $100,024
2025-05-30 WHALEY GLENN Chief Financial Officer — 25,000 $0.56 $14,000
2024-11-12 RUDICK RICHARD ALAN Director — 87,300 $1.15 $100,369
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
103.23
+5.28%
98.05
-1.18%
99.22
+14.68%
86.52
Research And Development
81.98
+2.42%
80.05
-3.81%
83.22
+16.78%
71.25
Selling General And Administration
21.25
+17.99%
18.01
+12.48%
16.01
+4.88%
15.26
General And Administrative Expense
21.25
+17.99%
18.01
+12.48%
16.01
+4.88%
15.26
Other Gand A
21.25
+17.99%
18.01
+12.48%
16.01
+4.88%
15.26
Other Operating Expenses
—
—
—
—
Total Expenses
103.23
+5.28%
98.05
-1.18%
99.22
+14.68%
86.52
Operating Income
-103.23
-5.28%
-98.05
+1.18%
-99.22
-14.68%
-86.52
Total Operating Income As Reported
-103.23
-5.28%
-98.05
+1.18%
-99.22
+16.96%
-119.49
EBITDA
-103.06
-5.25%
-97.92
+1.20%
-99.11
-14.66%
-86.44
Normalized EBITDA
-103.06
-5.25%
-97.92
+1.20%
-99.11
-85.36%
-53.47
Reconciled Depreciation
0.17
+25.37%
0.13
+20.72%
0.11
+44.16%
0.08
EBIT
-103.23
-5.28%
-98.05
+1.18%
-99.22
-14.68%
-86.52
Total Unusual Items
—
-4.80
0.00
+100.00%
-32.97
Total Unusual Items Excluding Goodwill
—
-4.80
0.00
+100.00%
-32.97
Special Income Charges
—
—
0.00
+100.00%
-32.97
Impairment Of Capital Assets
—
—
0.00
-100.00%
32.97
Net Income
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Pretax Income
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Net Non Operating Interest Income Expense
1.04
-69.32%
3.39
+10.24%
3.08
+195.39%
1.04
Net Interest Income
1.04
-69.32%
3.39
+10.24%
3.08
+195.39%
1.04
Interest Income Non Operating
1.04
-69.32%
3.39
+10.24%
3.08
+195.39%
1.04
Interest Income
1.04
-69.32%
3.39
+10.24%
3.08
+195.39%
1.04
Other Income Expense
5.02
+185.82%
-5.84
-330.48%
2.54
+107.26%
-34.93
Other Non Operating Income Expenses
5.02
+185.82%
-5.84
-330.48%
2.54
+229.39%
-1.96
Gain On Sale Of Security
—
-4.80
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Net Income From Continuing Operation Net Minority Interest
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Net Income From Continuing And Discontinued Operation
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Net Income Continuous Operations
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Normalized Income
-97.17
+3.32%
-100.51
-7.37%
-93.61
-7.06%
-87.44
Net Income Common Stockholders
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Diluted EPS
-0.62
+38.00%
-1.00
+52.61%
-2.11
+44.18%
-3.78
Basic EPS
-0.62
+38.00%
-1.00
+52.61%
-2.11
+44.18%
-3.78
Basic Average Shares
155.69
+55.42%
100.17
+126.03%
44.32
+39.29%
31.82
Diluted Average Shares
155.69
+55.42%
100.17
+126.03%
44.32
+39.29%
31.82
Diluted NI Availto Com Stockholders
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Line Item Trend 2023-12-31
Total Assets
54.30
Current Assets
52.53
Cash Cash Equivalents And Short Term Investments
46.67
Cash And Cash Equivalents
46.67
Other Short Term Investments
0.00
Receivables
2.48
Other Receivables
1.10
Taxes Receivable
1.37
Prepaid Assets
2.31
Other Current Assets
1.07
Total Non Current Assets
1.76
Net PPE
1.76
Gross PPE
1.76
Other Properties
1.76
Goodwill And Other Intangible Assets
—
Goodwill
—
Other Non Current Assets
—
Total Liabilities Net Minority Interest
25.37
Current Liabilities
24.73
Payables And Accrued Expenses
22.30
Payables
5.10
Accounts Payable
4.73
Other Payable
0.37
Current Accrued Expenses
17.20
Pensionand Other Post Retirement Benefit Plans Current
1.46
Current Debt And Capital Lease Obligation
0.69
Current Capital Lease Obligation
0.69
Other Current Liabilities
0.27
Total Non Current Liabilities Net Minority Interest
0.64
Long Term Debt And Capital Lease Obligation
0.64
Long Term Capital Lease Obligation
0.64
Stockholders Equity
28.93
Common Stock Equity
28.93
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
45.18
Ordinary Shares Number
45.18
Treasury Shares Number
0.00
Additional Paid In Capital
436.06
Retained Earnings
-410.89
Gains Losses Not Affecting Retained Earnings
3.76
Other Equity Adjustments
3.76
Total Equity Gross Minority Interest
28.93
Total Capitalization
28.93
Working Capital
27.80
Invested Capital
28.93
Total Debt
1.33
Capital Lease Obligations
1.33
Net Tangible Assets
28.93
Tangible Book Value
28.93
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-85.81
-1.23%
-84.77
-19.68%
-70.83
-8.73%
-65.14
Cash Flow From Continuing Operating Activities
-85.81
-1.23%
-84.77
-19.68%
-70.83
-8.73%
-65.14
Net Income From Continuing Operations
-97.17
+3.32%
-100.51
-7.37%
-93.61
+22.25%
-120.41
Depreciation Amortization Depletion
0.17
+25.37%
0.13
+20.72%
0.11
+44.16%
0.08
Depreciation And Amortization
0.17
+25.37%
0.13
+20.72%
0.11
+44.16%
0.08
Other Non Cash Items
0.50
-92.60%
6.72
—
—
Stock Based Compensation
8.86
+3.94%
8.53
+20.06%
7.10
-10.43%
7.93
Asset Impairment Charge
—
—
0.00
-100.00%
32.97
Operating Gains Losses
—
0.03
-94.26%
0.52
-89.01%
4.76
Net Foreign Currency Exchange Gain Loss
0.00
-100.00%
0.03
-94.26%
0.52
-89.01%
4.76
Change In Working Capital
1.84
+456.97%
0.33
-97.81%
15.05
+57.90%
9.53
Change In Prepaid Assets
—
—
3.86
-48.51%
7.49
Change In Payables And Accrued Expense
5.71
+433.18%
-1.72
-115.46%
11.09
+413.37%
2.16
Change In Accrued Expense
4.48
+192.12%
-4.86
-147.29%
10.28
+654.55%
1.36
Change In Payable
1.24
-60.67%
3.15
+284.94%
0.82
+2.25%
0.80
Change In Account Payable
1.24
-60.67%
3.15
+284.94%
0.82
+2.25%
0.80
Change In Other Current Assets
-3.16
-267.60%
1.89
-51.11%
3.86
—
Change In Other Current Liabilities
-0.71
-549.69%
0.16
+65.63%
0.10
+177.42%
-0.12
Investing Cash Flow
-0.16
+39.02%
-0.26
-102.79%
9.46
+197.14%
-9.74
Cash Flow From Continuing Investing Activities
-0.16
+39.02%
-0.26
-102.79%
9.46
+197.14%
-9.74
Net PPE Purchase And Sale
-0.16
+39.02%
-0.26
+20.96%
-0.33
-198.21%
-0.11
Purchase Of PPE
-0.16
+39.02%
-0.26
+20.96%
-0.33
-198.21%
-0.11
Capital Expenditure
-0.16
+39.02%
-0.26
+20.96%
-0.33
-198.21%
-0.11
Net Investment Purchase And Sale
—
0.00
-100.00%
9.80
+201.73%
-9.63
Purchase Of Investment
—
—
—
-9.63
Sale Of Investment
—
0.00
-100.00%
9.80
—
Financing Cash Flow
65.58
-12.03%
74.54
+7115.97%
1.03
-98.92%
95.76
Cash Flow From Continuing Financing Activities
65.58
-12.03%
74.54
+7115.97%
1.03
-98.92%
95.76
Net Common Stock Issuance
65.39
+34138.22%
0.19
-77.61%
0.85
-97.85%
39.58
Proceeds From Stock Option Exercised
0.18
+136.36%
0.08
-57.22%
0.18
-3.74%
0.19
Net Other Financing Charges
—
74.27
—
—
Changes In Cash
-20.39
-94.39%
-10.49
+82.61%
-60.33
-389.02%
20.88
Effect Of Exchange Rate Changes
0.20
+139.65%
-0.52
-297.33%
0.26
+126.38%
-0.99
Beginning Cash Position
35.67
-23.58%
46.67
-56.28%
106.75
+22.89%
86.86
End Cash Position
15.48
-56.59%
35.67
-23.58%
46.67
-56.28%
106.75
Free Cash Flow
-85.97
-1.10%
-85.03
-19.49%
-71.16
-9.05%
-65.26
Common Stock Issuance
65.39
+34138.22%
0.19
-77.61%
0.85
-97.85%
39.58
Issuance Of Capital Stock
65.39
+34138.22%
0.19
-77.61%
0.85
-99.11%
95.57
Net Preferred Stock Issuance
—
—
0.00
-100.00%
55.99
Preferred Stock Issuance
—
—
0.00
-100.00%
55.99
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category